Jane C Davies Selected Research

ivacaftor drug combination tezacaftor

12/2022	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
7/2022	An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.
1/2022	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
1/2021	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
10/2018	VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
1/2018	Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
11/2017	Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jane C Davies Research Topics

Disease

60	Cystic Fibrosis (Mucoviscidosis) 12/2022 - 09/2005
14	Infections 01/2022 - 07/2004
10	Lung Diseases (Lung Disease) 12/2021 - 09/2008
8	Inflammation (Inflammations) 12/2021 - 03/2013
3	Persistent Infection 01/2020 - 05/2009
3	Respiratory Tract Diseases (Respiratory Tract Disease) 09/2018 - 03/2013
2	Multiple Sclerosis 01/2022 - 11/2017
2	Coinfection 01/2022 - 10/2021
2	Cough 01/2021 - 01/2021
2	Weight Gain 08/2018 - 06/2013
2	Pseudomonas Infections 12/2017 - 01/2017
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 11/2021
1	Headache (Headaches) 11/2021
1	Primary Headache Disorders 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Necrosis 01/2020
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2020
1	Constipation 01/2018
1	Vitamin D Deficiency 01/2018
1	Intestinal Obstruction (Obstruction, Intestinal) 01/2018
1	Kaposi Varicelliform Eruption (Eczema Herpeticum) 01/2018
1	Chronic Cough 01/2018
1	Communicable Diseases (Infectious Diseases) 12/2017
1	Fibrosis (Cirrhosis) 01/2017
1	Bronchiectasis 07/2011
1	Airway Remodeling 06/2007

Drug/Important Bio-Agent (IBA)

15	ivacaftorIBA 07/2022 - 06/2013
11	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2021 - 11/2010
10	Pharmaceutical PreparationsIBA 07/2022 - 09/2005
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2004
7	ivacaftor drug combination tezacaftorIBA 12/2022 - 11/2017
7	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 04/2006
6	Biomarkers (Surrogate Marker)IBA 01/2018 - 04/2007
5	ChloridesIBA 12/2022 - 10/2018
3	Tobramycin (Nebcin)FDA LinkGeneric 01/2022 - 09/2005
3	lumacaftorIBA 01/2021 - 01/2015
3	tezacaftorIBA 01/2021 - 11/2017
2	elexacaftorIBA 12/2022 - 07/2022
2	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 11/2017
2	posaconazole FDA Link 11/2021 - 01/2020
2	AlginatesIBA 10/2020 - 01/2017
2	OligosaccharidesIBA 10/2020 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 09/2015
2	Liposomes (Liposome)IBA 12/2015 - 09/2015
2	LipidsIBA 12/2013 - 07/2010
1	Peptides (Polypeptides)IBA 01/2022
1	Epithelial Sodium ChannelsIBA 01/2022
1	TabletsIBA 11/2021
1	SodiumIBA 11/2021
1	riociguatIBA 11/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	hypothiocyanous acidIBA 12/2020
1	Hypochlorous Acid (Hypochlorite)IBA 12/2020
1	Oxidants (Oxidizing Agents)IBA 12/2020
1	PowdersIBA 10/2020
1	Anti-Infective Agents (Microbicides)IBA 10/2020
1	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2020
1	EnzymesIBA 01/2020
1	Expectorants (Mucolytics)IBA 01/2020
1	InterleukinsIBA 01/2020
1	Terbinafine (Lamisil)FDA LinkGeneric 01/2020
1	ProdrugsIBA 01/2020
1	prolyl-glycyl-prolineIBA 01/2020
1	leukotriene A4 hydrolaseIBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	CytokinesIBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2020
1	Nitric Oxide DonorsIBA 01/2020
1	C-Reactive ProteinIBA 01/2020
1	VX-659IBA 10/2018
1	GasesIBA 09/2018
1	Antimicrobial PeptidesIBA 01/2018
1	Vitamin D FDA LinkGeneric 01/2018
1	clonidine-displacing substance (ClDS)IBA 01/2018
1	Interleukin-8 (Interleukin 8)IBA 01/2018
1	Aspartic Acid (Aspartate)FDA Link 01/2018
1	Alanine Transaminase (SGPT)IBA 01/2018
1	N-(3-oxododecanoyl)homoserine lactoneIBA 12/2017
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2017
1	Levofloxacin (Levaquin)FDA Link 01/2017
1	AnionsIBA 01/2017
1	allyl sulfideIBA 01/2017
1	Amikacin (A.M.K)FDA LinkGeneric 01/2017
1	Cysteamine (Mercaptamine)FDA Link 01/2017
1	GalliumIBA 01/2017
1	Fosfomycin FDA Link 01/2017
1	Cyanides (Isocyanides)IBA 11/2014
1	AerosolsIBA 12/2013
1	Antiviral Agents (Antivirals)IBA 03/2013
1	Interleukin-17 (Interleukin 17)IBA 07/2011
1	Aligeron (AS 2)IBA 06/2007
1	AntibodiesIBA 05/2007

Therapy/Procedure

25	Therapeutics 07/2022 - 09/2008
1	Polypharmacy 07/2022
1	Precision Medicine 01/2021
1	High-Protein Diet 01/2020
1	Drug Therapy (Chemotherapy) 03/2018
1	Immunotherapy 01/2017